Bio-Rad has developed a COVID-19 ddPCR assay designed to be a powerful nucleic acid tool in the battle against COVID-19, with sensitivity and precision beyond that of qPCR assays.
The 2019-nCoV CDC ddPCR Triplex Probe Assay is a quantitative assay optimized for use on our QX200 and QXDx Droplet Digital PCR Systems using the 1-Step RT-ddPCR Advanced Kit for Probes and SARS-CoV-2 positive and negative standards. The 2019-nCoV CDC ddPCR Assay is currently for research use only (EUA pending for diagnostic use).
High sensitivity and precision in low viral abundance samples
Resistant to inhibition often seen in RT-PCR testing
Single-well test – 3 sequences aligned to CDC markers: SARS-CoV-2 N1 and N2 genes, human RPP30 gene
Available in 200 reactions (1,000 reactions coming soon)
Bio-Rad’s Droplet Digital PCR Systems provide ultrasensitive and absolute nucleic acid quantification. Droplet Digital PCR is particularly useful for low-abundance targets, targets in complex backgrounds, or monitoring subtle changes in target levels that cannot be detected with real-time PCR.
Simplifies ddPCR workflow and ensures consistency
Generates droplets for 96 ddPCR reactions in 45 minutes
One AutoDG Instrument can supply 4–5 droplet readers
HEPA-filtered enclosure reduces contamination risk